Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Republic of the Congo has witnessed significant growth in recent years.
Customer preferences: The demand for Anti-Hypertensive Drugs in Republic of the Congo is primarily driven by the increasing prevalence of hypertension among the population. Hypertension is a major health concern in the country, with a significant proportion of the population suffering from the condition. As a result, there is a high demand for Anti-Hypertensive Drugs to manage the condition and prevent complications.
Trends in the market: The Anti-Hypertensive Drugs market in Republic of the Congo is characterized by the dominance of generic drugs. This is due to the high cost of branded drugs, which are often unaffordable for the majority of the population. As a result, generic drugs are preferred due to their lower cost and widespread availability. Furthermore, there is a growing trend towards the use of combination therapy, where two or more drugs are used together to manage hypertension. This is because combination therapy is often more effective in managing hypertension than monotherapy.
Local special circumstances: One of the major challenges facing the Anti-Hypertensive Drugs market in Republic of the Congo is the low level of awareness about hypertension among the population. Many people are unaware of the condition and its implications, which often leads to delayed diagnosis and treatment. Additionally, there is a lack of healthcare infrastructure in the country, which makes it difficult for people to access healthcare services.
Underlying macroeconomic factors: The underlying macroeconomic factors driving the growth of the Anti-Hypertensive Drugs market in Republic of the Congo include the increasing population and the growing burden of non-communicable diseases. The population of the country is growing rapidly, which is leading to an increase in the number of people suffering from hypertension. Additionally, the country is experiencing a shift towards urbanization and a sedentary lifestyle, which are contributing to the growing burden of non-communicable diseases such as hypertension.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
